- In April 2024, Roche Diagnostics launched an advanced prostate-specific antigen (PSA) blood test with enhanced sensitivity and specificity to detect early-stage prostate cancer. This next-generation diagnostic solution is designed to reduce false positives and improve early intervention outcomes, reinforcing Roche’s leadership in precision oncology diagnostics within the global prostate cancer diagnostics market
- In March 2024, Exact Sciences Corporation announced the expansion of its prostate cancer diagnostic portfolio with a novel genomic testing platform aimed at predicting disease aggressiveness. This development leverages artificial intelligence and genomic sequencing to aid in personalized treatment planning, supporting the trend toward precision medicine
- In February 2024, Siemens Healthineers unveiled an integrated imaging and diagnostic platform that combines MRI and AI-driven analytics to detect and monitor prostate cancer progression with greater accuracy. The system, now being deployed in major hospitals across Europe and North America, marks a significant advancement in non-invasive diagnostic capabilities
- In January 2024, Bio-Techne Corporation, through its Exosome Diagnostics division, introduced a urine-based liquid biopsy test for prostate cancer detection that eliminates the need for invasive procedures. The test is gaining adoption across U.S. urology clinics and specialty centers, highlighting the shift toward non-invasive, patient-friendly diagnostic approaches
- In December 2023, OPKO Health Inc. partnered with a leading academic medical center to conduct large-scale clinical trials for its 4Kscore Test, a blood-based biomarker assay used to assess the risk of aggressive prostate cancer. This strategic collaboration aims to expand the test’s clinical utility and regulatory approvals across additional global markets
